KR970701710A - 벤젠축합 헤테로환 유도체 및 그 용도(benzene-condensed hetero ring derivatives and their uses) - Google Patents
벤젠축합 헤테로환 유도체 및 그 용도(benzene-condensed hetero ring derivatives and their uses) Download PDFInfo
- Publication number
- KR970701710A KR970701710A KR1019960704937A KR19960704937A KR970701710A KR 970701710 A KR970701710 A KR 970701710A KR 1019960704937 A KR1019960704937 A KR 1019960704937A KR 19960704937 A KR19960704937 A KR 19960704937A KR 970701710 A KR970701710 A KR 970701710A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- group
- carbon atoms
- phenyl
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000002541 furyl group Chemical group 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000001544 thienyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010073391 Platelet dysfunction Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 230000003836 peripheral circulation Effects 0.000 claims 2
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- -1 (substituted) phenyl Chemical group 0.000 claims 1
- SQAINHDHICKHLX-UHFFFAOYSA-N 1-naphthaldehyde Chemical group C1=CC=C2C(C=O)=CC=CC2=C1 SQAINHDHICKHLX-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004087 circulation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 102000009079 Epoprostenol Receptors Human genes 0.000 abstract 1
- 108010073099 Epoprostenol Receptors Proteins 0.000 abstract 1
- 101150100032 Tbxa2r gene Proteins 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
강력한 TXA2 수용체길항작용과 PGI2 수용체 아고니스트작용을 가지고 있으며, TXA2가 관여하고 있는 질병의 치료 및 예방에 유효한 신규화합물이 개시되어 있다. 본 발명의 화합물은, 하기 일반식(I)로 표시된다.
(또 식중, 각 기호의 의미는 명세서 기재와 같다.)
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 일반식(I)〔식(I)중 R1은 -X-(CH2)n COOR3(식중 X는 -O-, -S-, 또는 -CH2-이고, R3은 수소, 탄소수 1~5의 저급알킬기, 약리학적으로 허용되는 염을 제공하는 원자 또는 기이고, n은 1~3의 정수를 나타낸다)이고, R2는 i) -CR4=CR5-O-, ii) -CR5=CR4-O-, 또는 (iii) -NR4-CR5R6-CHR7-(식중 R4는 -(CH2)m-Y-R8(식중 m은 1~4의 정수를 나타낸다.) y는 1) -O-, 2) -CH2-, 3) -S(O) p-(p는 0~2의 정수를 나타낸다), 4) -CO-, 5) -CH(OH)-, 6) -NR9SO2-, (식중 R9는 a) 수소, b) 탄소수 1~5의 알킬, c) (치환되어 있어도 좋은)페닐 또는, d) (치환되어 있어도 좋은)페닐기로 치환된 탄소수 1~5의 알킬이다), 7) -NR9CO-(R9는 상기한 정의와 같다), 8) -CONR9-(R9는 상기한 정의와 같다), 9) -NR9-(R9는 상기한 정의와 같다), 10) -O-N=CR9-(R9는 상기한 정의와 같다) 또는 11) 식(Ⅱ)이고, R8은 1) 페닐, 티에닐, 푸릴, 나프틸 또는 탄소수 3~8의 시클로알킬, 2) 치환페닐, 치환티에틸, 치환푸릴, 또는 치환나프틸, 3) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프털기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 1~5의 알킬, 4) (치환되어 있어도 좋은)페닐기, (치횐되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 2~5의 알케닐, 5) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 3~5의 알케닐, 6) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 2~8의 알콕시알킬, 7) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 1~5의 히드록시알킬, 8) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 2~8의 알킬티오알킬 또는 9) (치환되어 있어도 좋은)페닐기, (치환되어 있어도 좋은)티에닐기, (치환되어 있어도 좋은)푸릴기, (치환되어 있어도 좋은)나프틸기, 탄소수 3~8의 시클로알킬기, 페녹시기에서 선택된 1개 또는 2개의 치환기로 치환된 탄소수 1~5의 아미노알킬 10) -CH2-C (O)-R10(R10은(치환되어 있어도 좋은) 페닐기, 1개 또는 2개의 (치환되어 있어도 좋은) 페닐기로 치환된 탄소수 1~5의 알킬기이다)이다)이고, R5는 1) 수소, 2) 탄소수 1~5의 알킬, 3) 탄소수 1~5의 시클로알킬 또는 아세톡시알킬, 4) 1개 또는 2개의(치환되어 있어도 좋은)페닐기로 치환된 탄소수 1~5의 알킬, 5) 1개 또는 2개의(치환되어 있어도 좋은)페닐기로 치환된 탄소수 2~8의 알콕시알킬이고, R6, R7은 수소 또는 R6과 R7에 공유결합해서 이중결합을 표시한다)이다〕로 표시되는 벤젠축합 헤테로환 유도체.
- 제1항에 있어서, X가 -O-인 화합물.
- 제1항 또는 제2항에 있어서, R2가 -CR4=CR-O- 또는 -CR5=CR4-O-인 화합물.
- 제1항 또는 제2항에 있어서, R2가 -NR4-CR5R6-CHR7-인 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, Y가 -O- 또는 -CH2-인 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, Y가 -S(O)p-인 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, Y가 -NR9SO2- 또는 -NR9CO-인 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, Y가 -NR9- 또는 -CONR9-인 화합물.
- 제1항 내지 제8항의 어떤 한 항에 기재된 화합물을 유효성분으로 함유하는 의약 조성물.
- 제1항 내지 제8항의 어떤 한 항에 기재된 화합물을 유효성분으로 함유하는 트롬복산A2수용체 길항약.
- 제1항 내지 제8항의 어떤 한 항에 기재된 화합물을 유효성분으로 함유하는 고혈압증, 혈전증, 허혈성심질환, 뇌순환장해, 말초순환장애, 동맥경화증, 혈소판기능장해, 고지혈증, 신장염, 천식의 치료 및 예방약.
- 제1항 내지 제8항의 어떤 한 항에 기재된 화합물의 트롬복산A2수용체 길항약으로서의 용도.
- 제1항 내지 제8항의 어떤 한 항에 기재된 화합물의 고혈압증, 혈전증, 허혈성심질환, 뇌순환장애, 말초순환장해, 동맥경화증, 혈소판기능장해, 고지혈증, 신장염, 천식의 치료 및 예방약으로서의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP95-788 | 1995-01-06 | ||
JP78895 | 1995-01-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970701710A true KR970701710A (ko) | 1997-04-12 |
KR100436812B1 KR100436812B1 (ko) | 2004-08-31 |
Family
ID=11483438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960704937A KR100436812B1 (ko) | 1995-01-06 | 1996-01-08 | 벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물 |
Country Status (9)
Country | Link |
---|---|
US (2) | US6043264A (ko) |
EP (1) | EP0751126A4 (ko) |
KR (1) | KR100436812B1 (ko) |
CN (1) | CN1092639C (ko) |
AU (1) | AU714054B2 (ko) |
FI (1) | FI963477A (ko) |
NO (1) | NO963706L (ko) |
TW (1) | TW430662B (ko) |
WO (1) | WO1996020925A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2742047B1 (fr) * | 1995-12-06 | 1998-01-16 | Oreal | Compositions de teinture des fibres keratiniques contenant des derives n-substitues de la 4-hydroxy indoline, nouveaux derives, leur procede de synthese, leur utilisation pour la teinture, et procede de teinture |
TW416953B (en) | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
EP0988289A2 (en) * | 1997-06-05 | 2000-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, their production and use |
JP4834224B2 (ja) | 1999-03-05 | 2011-12-14 | デューク ユニバーシティ | C16不飽和fp−選択的プロスタグランジン類縁体 |
US6894175B1 (en) * | 1999-08-04 | 2005-05-17 | The Procter & Gamble Company | 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020013294A1 (en) * | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
JP2001354671A (ja) * | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
FR2827287B1 (fr) * | 2001-07-13 | 2003-10-31 | Servier Lab | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2457054C (en) * | 2001-08-10 | 2011-10-11 | Nippon Chemiphar Co., Ltd. | Activator of peroxisome proliferator-activated receptor .delta. |
DK1445258T3 (da) * | 2001-10-12 | 2009-10-12 | Nippon Chemiphar Co | Aktivator for peroxisomproliferator-aktiveret receptor delta |
JP4127678B2 (ja) * | 2004-02-27 | 2008-07-30 | 株式会社東芝 | 半導体装置及びそのプログラミング方法 |
JPWO2007004733A1 (ja) * | 2005-07-06 | 2009-01-29 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
PL2014652T3 (pl) * | 2006-04-18 | 2015-02-27 | Nippon Chemiphar Co | Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów |
WO2009128558A1 (ja) * | 2008-04-15 | 2009-10-22 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
KR20120099378A (ko) * | 2009-08-14 | 2012-09-10 | 닛뽕 케미파 가부시키가이샤 | 염증 또는 에너지 대사/생산 관련 질환의 치료 또는 예방을 위한 ppar 델타 리간드의 용도 |
CN106478606B (zh) * | 2016-09-21 | 2019-05-10 | 沈阳药科大学 | N-取代吲哚类衍生物及其应用 |
KR20190047279A (ko) | 2017-10-27 | 2019-05-08 | 삼성에스디에스 주식회사 | 차량에 구비된 카메라를 이용한 차량 주변 영상 합성 방법 및 그 장치 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933351A (en) * | 1983-10-31 | 1990-06-12 | Merck Frosst Canada, Inc. | Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis |
CA1281325C (en) * | 1984-06-20 | 1991-03-12 | Patrice C. Belanger | Benzofuran derivatives |
GB8906032D0 (en) * | 1988-04-14 | 1989-04-26 | Ici America Inc | Hetera-aliphatic carboxamides |
FR2645537B1 (fr) * | 1989-04-05 | 1994-03-04 | Fabre Medicament Pierre | Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique |
CA2085844A1 (en) * | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
JP2691679B2 (ja) * | 1992-07-21 | 1997-12-17 | 小野薬品工業株式会社 | オキシム誘導体およびそれを含有する医薬品 |
GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
CZ82295A3 (en) * | 1994-04-01 | 1995-12-13 | Lilly Co Eli | Derivative of 1h-indole-3-glyoxylamide and a pharmaceutical composition containing thereof |
FR2729147A1 (fr) * | 1995-01-11 | 1996-07-12 | Adir | Nouveaux composes (hetero) cycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JPH11503445A (ja) * | 1995-04-10 | 1999-03-26 | 藤沢薬品工業株式会社 | cGMP−PDE阻害剤としてのインドール誘導体 |
FR2734814B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
1996
- 1996-01-08 AU AU43572/96A patent/AU714054B2/en not_active Ceased
- 1996-01-08 KR KR1019960704937A patent/KR100436812B1/ko not_active IP Right Cessation
- 1996-01-08 WO PCT/JP1996/000011 patent/WO1996020925A1/ja not_active Application Discontinuation
- 1996-01-08 EP EP96900184A patent/EP0751126A4/en not_active Withdrawn
- 1996-01-08 US US08/700,477 patent/US6043264A/en not_active Expired - Fee Related
- 1996-01-08 CN CN96190162A patent/CN1092639C/zh not_active Expired - Fee Related
- 1996-02-28 TW TW085102335A patent/TW430662B/zh active
- 1996-09-05 NO NO963706A patent/NO963706L/no unknown
- 1996-09-05 FI FI963477A patent/FI963477A/fi unknown
-
2000
- 2000-01-13 US US09/482,279 patent/US6323235B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0751126A4 (en) | 1998-05-13 |
AU714054B2 (en) | 1999-12-16 |
AU4357296A (en) | 1996-07-24 |
CN1092639C (zh) | 2002-10-16 |
TW430662B (en) | 2001-04-21 |
EP0751126A1 (en) | 1997-01-02 |
WO1996020925A1 (fr) | 1996-07-11 |
FI963477A0 (fi) | 1996-09-05 |
NO963706L (no) | 1996-11-06 |
US6043264A (en) | 2000-03-28 |
NO963706D0 (no) | 1996-09-05 |
FI963477A (fi) | 1996-11-04 |
US6323235B1 (en) | 2001-11-27 |
KR100436812B1 (ko) | 2004-08-31 |
CN1148381A (zh) | 1997-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970701710A (ko) | 벤젠축합 헤테로환 유도체 및 그 용도(benzene-condensed hetero ring derivatives and their uses) | |
FR16C1001I2 (fr) | "derive de 2-oxo-1-pyrrolidine et ses applications pharmaceutiques" | |
KR900014367A (ko) | 피롤리딘 유도체 | |
EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
WO2002098857A8 (en) | New indole derivatives with 5-ht6 receptor affinity | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
HUP9800417A2 (hu) | 5-Szubsztituált-3-(1,2,3,6-tetrahidro-piridin-4-il)-1H-indolok és 5-szubsztituált-3-(piridin-4-il)-1H-indolok, alkalmazásuk mint új 5-HT agonisták, a vegyületeket tartalmazó gyógyszerkészítmények | |
CY1108031T1 (el) | Υποκατασταθεντα παραγωγα της καρβοστυριλης ως συναγωνιστες υποδοχεων υποτυπου 5-ht 1a | |
KR970042506A (ko) | 신규한 2-나프타미드 유도체와 이의 치료제로서의 사용 | |
ATE121406T1 (de) | Trizyklische lactamderivate und pharmazeutische zusammensetzungen, die sie enthalten. | |
KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
RU2006124863A (ru) | Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера | |
KR940702491A (ko) | 옥사졸리돈 유도체 | |
KR960003719A (ko) | 녹내장 치료제 및 안압 강하제 | |
FR2669030B1 (fr) | Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
KR910019978A (ko) | 스피로 디벤조수베란 유도체 | |
KR930021629A (ko) | 피페라진 유도체 | |
KR970064604A (ko) | 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도 | |
HUP9702481A2 (hu) | Új N-benzil-piperazin-vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
KR950008502A (ko) | 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제 | |
EP0769496A4 (en) | 2,3-DIHYDROBENZOFURAN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | |
KR950008446A (ko) | 시클로헥산 유도체 | |
KR960700050A (ko) | 2,3-디히드로벤조푸란 유도체(2,3-dihydrobenzofuran derivative) | |
KR960702445A (ko) | 1-(2-벤조이미다졸일)-1, 5- 디아자시클로옥탄 유도체(1-(2-benzimidazo-lyl)-1,5-diazacyclooctane compounds) | |
DE3650347T2 (de) | 1,4-Benzodioxanderivate, Verfahren zu deren Herstellung, pharmakologische Zusammensetzung und deren Verwendung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |